184 related articles for article (PubMed ID: 26758488)
21. GH Therapy and first final height data in Noonan-like syndrome with loose anagen hair (Mazzanti syndrome).
Mazzanti L; Tamburrino F; Scarano E; Perri A; Vestrucci B; Guidetti M; Rossi C; Tartaglia M
Am J Med Genet A; 2013 Nov; 161A(11):2756-61. PubMed ID: 24124081
[TBL] [Abstract][Full Text] [Related]
22. Diagnosis and growth hormone (GH) therapy in children with GH deficiency: experience in King Chulalongkorn Memorial Hospital, Thailand.
Wacharasindhu S; Supornsilchai V; Aroonparkmongkol S; Srivuthana S
J Med Assoc Thai; 2007 Oct; 90(10):2047-52. PubMed ID: 18041422
[TBL] [Abstract][Full Text] [Related]
23. Neurofibromatosis/Noonan phenotype: a variable feature of type 1 neurofibromatosis.
Colley A; Donnai D; Evans DG
Clin Genet; 1996 Feb; 49(2):59-64. PubMed ID: 8740913
[TBL] [Abstract][Full Text] [Related]
24. Incidence and Outcomes of Pituitary Microadenomas in Children with Short Stature/Growth Hormone Deficiency.
Derrick KM; Gomes WA; Gensure RC
Horm Res Paediatr; 2018; 90(3):151-160. PubMed ID: 30261514
[TBL] [Abstract][Full Text] [Related]
25. Abnormal growth in noonan syndrome: genetic and endocrine features and optimal treatment.
Padidela R; Camacho-Hübner C; Attie KM; Savage MO
Horm Res; 2008; 70(3):129-36. PubMed ID: 18663312
[TBL] [Abstract][Full Text] [Related]
26. LEOPARD syndrome (PTPN11, T468M) in three boys fulfilling neurofibromatosis type 1 clinical criteria.
Carcavilla A; Pinto I; Muñoz-Pacheco R; Barrio R; Martin-Frías M; Ezquieta B
Eur J Pediatr; 2011 Aug; 170(8):1069-74. PubMed ID: 21365175
[TBL] [Abstract][Full Text] [Related]
27. Neurofibromatosis-Noonan syndrome and acute lymphoblastic leukemia: a report of two cases.
Klopfenstein KJ; Sommer A; Ruymann FB
J Pediatr Hematol Oncol; 1999; 21(2):158-60. PubMed ID: 10206464
[TBL] [Abstract][Full Text] [Related]
28. Noonan syndrome: growth to growth hormone - the experience of observational studies.
Ranke MB
Horm Res; 2009 Dec; 72 Suppl 2():36-40. PubMed ID: 20029235
[TBL] [Abstract][Full Text] [Related]
29. Neurofibromatosis-Noonan syndrome: molecular evidence of the concurrence of both disorders in a patient.
Bertola DR; Pereira AC; Passetti F; de Oliveira PS; Messiaen L; Gelb BD; Kim CA; Krieger JE
Am J Med Genet A; 2005 Jul; 136(3):242-5. PubMed ID: 15948193
[TBL] [Abstract][Full Text] [Related]
30. Partial empty sella syndrome, GH deficiency and transient central adrenal insufficiency in a patient with NF1.
Kyritsi EM; Hasiotou M; Kanaka-Gantenbein C
Endocrine; 2020 Aug; 69(2):377-385. PubMed ID: 32519328
[TBL] [Abstract][Full Text] [Related]
31. A new nonsense mutation in the NF1 gene with neurofibromatosis-Noonan syndrome phenotype.
Yimenicioğlu S; Yakut A; Karaer K; Zenker M; Ekici A; Carman KB
Childs Nerv Syst; 2012 Dec; 28(12):2181-3. PubMed ID: 22965773
[TBL] [Abstract][Full Text] [Related]
32. Noonan syndrome presenting growth hormone neurosecretory dysfunction.
Tanaka K; Sato A; Naito T; Kuramochi K; Itabashi H; Takemura Y
Intern Med; 1992 Jul; 31(7):908-11. PubMed ID: 1450501
[TBL] [Abstract][Full Text] [Related]
33. Effect on adult height of pubertal growth hormone retesting and withdrawal of therapy in patients with previously diagnosed growth hormone deficiency.
Zucchini S; Pirazzoli P; Baronio F; Gennari M; Bal MO; Balsamo A; Gualandi S; Cicognani A
J Clin Endocrinol Metab; 2006 Nov; 91(11):4271-6. PubMed ID: 16912138
[TBL] [Abstract][Full Text] [Related]
34. Exclusion of allelism of Noonan syndrome and neurofibromatosis-type 1 in a large family with Noonan syndrome-neurofibromatosis association.
Bahuau M; Flintoff W; Assouline B; Lyonnet S; Le Merrer M; Prieur M; Guilloud-Bataille M; Feingold N; Munnich A; Vidaud M; Vidaud D
Am J Med Genet; 1996 Dec; 66(3):347-55. PubMed ID: 8985499
[TBL] [Abstract][Full Text] [Related]
35. Increased rate of missense/in-frame mutations in individuals with NF1-related pulmonary stenosis: a novel genotype-phenotype correlation.
Ben-Shachar S; Constantini S; Hallevi H; Sach EK; Upadhyaya M; Evans GD; Huson SM
Eur J Hum Genet; 2013 May; 21(5):535-9. PubMed ID: 23047742
[TBL] [Abstract][Full Text] [Related]
36. Congenital absence of the superior oblique tendon in Noonan-neurofibromatosis syndrome.
Sugumaran HK; Pappas JG; Kodsi SR
J AAPOS; 2011 Dec; 15(6):593-4. PubMed ID: 22153407
[TBL] [Abstract][Full Text] [Related]
37. Neurofibromatosis-Noonan syndrome: case report and clinicopathogenic review of the Neurofibromatosis-Noonan syndrome and RAS-MAPK pathway.
Reig I; Boixeda P; Fleta B; Morenoc C; Gámez L; Truchuelo M
Dermatol Online J; 2011 Apr; 17(4):4. PubMed ID: 21549079
[TBL] [Abstract][Full Text] [Related]
38. Abnormal growth in noonan syndrome: the challenge of optimal therapy.
Savage MO; Padidela R; Kirk JM; Malaquias AC; Jorge AA
Pediatr Endocrinol Rev; 2009 Jun; 6 Suppl 4():523-8. PubMed ID: 19550387
[TBL] [Abstract][Full Text] [Related]
39. A case of neurofibromatosis-Noonan syndrome with a central giant cell granuloma.
Yazdizadeh M; Tapia JL; Baharvand M; Radfar L
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2004 Sep; 98(3):316-20. PubMed ID: 15356469
[TBL] [Abstract][Full Text] [Related]
40. Neurofibromatosis with fully expressed Noonan syndrome.
Abuelo DN; Meryash DL
Am J Med Genet; 1988 Apr; 29(4):937-41. PubMed ID: 3135755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
